Where Science Meets Opportunity
Accelerating Growth in Biotech and Life Sciences
Karnala Sai Chirner New Town (KSCNT) is strategically positioned to emerge as a global hub for biotechnology and life sciences. With India’s established leadership in pharmaceuticals and biopharma, KSCNT offers cutting-edge infrastructure and access to international markets through its port connectivity. Whether you are pioneering biopharmaceuticals, conducting advanced R&D, or manufacturing vaccines, KSCNT is your ideal partner in driving innovation and growth in life sciences.
Why KSCNT for Biotechnology and Life Sciences?
India’s Biopharma Leadership
With a 20% share of the global supply of generic medicines and 60% of global vaccine production, India provides a strong foundation for biotech firms to thrive.
Strategic Location
KSCNT’s proximity to JNPT Port offers seamless access to global markets for exporting high-value biopharmaceuticals, vaccines, and biologics.
R&D Collaboration
Access to leading academic institutions and research centers in Maharashtra ensures a steady pipeline of skilled talent and innovation.
Government Incentives
Benefit from supportive policies such as the Production Linked Incentive (PLI) Scheme and 100% FDI in biopharma.
Opportunities at KSCNT
Biopharma Parks for Vaccine and Biologics Production
KSCNT can host state-of-the-art biopharma parks equipped for large-scale vaccine and biologics manufacturing.
- Facilities for manufacturing biologics, biosimilars, and advanced therapies.
- Cold chain infrastructure for safe storage and transportation of sensitive products.
- Export-focused production with proximity to JNPT Port.
Research and Development Hubs for New Therapies and Regenerative Medicine
KSCNT provides a conducive environment for R&D in cutting-edge areas like gene therapies and regenerative medicine.
- Incubation centers for biotech startups.
- Collaboration with academic institutions for clinical trials and translational research.
- Innovation labs equipped with advanced technologies for biotech R&D.
Collaboration with Academic Institutions for Skill Development and Innovation
KSCNT promotes partnerships with academic institutions to develop a skilled workforce and drive innovation in life sciences.
- Industry-academia tie-ups for biotechnology and pharmaceutical education.
- Training programs focused on advanced manufacturing techniques and R&D methodologies.
- Establishment of Centers of Excellence in biotechnology.
Growth Drivers
- India’s Biopharma Market Leadership:
India is the third-largest pharmaceutical manufacturer globally and a leader in biopharma production. - Rising Global Demand for Biopharmaceuticals:
Growing demand for vaccines, biosimilars, and gene therapies creates vast opportunities for expansion. - Strategic Export Potential:
KSCNT’s connectivity to international markets positions it as a prime location for exporting high-value biotech products. - Supportive Ecosystem:
The Indian government’s focus on innovation through schemes like the PLI and National Biopharma Mission fosters growth in the sector.
What Makes KSCNT Unique?
Integrated Biotech Infrastructure
KSCNT offers plug-and-play facilities for biotech manufacturing, R&D, and clinical trials.
Seamless Global Connectivity
Proximity to JNPT Port ensures cost-effective logistics for exporting biopharmaceuticals to key markets.
Skilled Talent Pool
Collaboration with local universities and research institutes ensures access to trained professionals in biotechnology and life sciences.
Sustainability Focus
KSCNT’s commitment to sustainability aligns with global ESG standards, attracting impact-driven biotech investors.
Government Initiatives Supporting Biotechnology
- Production Linked Incentive (PLI) Scheme:
Financial incentives to boost domestic manufacturing of biopharmaceuticals, APIs, and advanced therapies. - National Biopharma Mission:
Aims to accelerate the development of biopharmaceuticals through innovation and capacity building. - 100% FDI:
Automatic route for FDI in biopharma and life sciences to attract global players. - Clinical Trial Reforms:
Simplified regulations and faster approvals for clinical trials to encourage R&D investments.